Upper respiratory tract infection was reported in 13.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 12.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.